Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Protagen AG announces € 10.0 Million for second round of finance totaling

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis announced today a second round of finance totalling a volume of € 10.0 Million.

7 Sep 2010

Dilemmas created for healthcare professionals by medicinal use of cannabis

Nurses have a responsibility to respect and support patients who use cannabis for medicinal purposes, but must stay within the law and follow professional guidance at all times, according to a research review in the September issue of the Journal of Clinical Nursing.

3 Sep 2010

'Aspartame danger' myths

Heard the one about how aspartame single-handedly caused the Gulf War syndrome? In recent years, outlandish allegations – often spread via the Internet by individuals who have little scientific or medical expertise – have tried to link the low-calorie sweetener to every ailment ranging from Multiple Sclerosis and Parkinson's disease to cancer and weight gain. However, the overwhelming body of scientific evidence via more than three decades of research and over 200 studies demonstrate that aspartame is safe.

3 Sep 2010

Study demonstrates safety of cord blood stem cell transplantation protocol to treat neurological conditions

In a new peer-reviewed article published by the Journal of Translational Medicine, scientists from Beike Biotechnology,China's leading stem cell research and regenerative medicine company, and Medistem, Inc.,reported positive safety data in 114 patients who were treated by doctors at Nanshan Affiliated Hospital of Guangdong Medical College (Shenzhen Nanshan Hospital) in Shenzhen using Beike's proprietary cord blood stem cell transplantation protocol.

3 Sep 2010

Benefit of delaying cognitive decline comes at the cost of more rapid dementia progression

New research shows that mentally stimulating activities such as crossword puzzles, reading and listening to the radio may, at first, slow the decline of thinking skills but speed up dementia later in old age. The research is published in the September 1, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

2 Sep 2010

CIHR announces recommendations on multiple sclerosis research priorities

On Thursday, August 26, the Canadian Institutes of Health Research (CIHR), in collaboration with the MS Society of Canada, convened a meeting of leading North American experts in multiple sclerosis (MS) to identify research priorities for Canada in this area.

2 Sep 2010

New research clinic in Edinburgh to improve outcomes for multiple sclerosis sufferers

A research clinic for multiple sclerosis patients is being set up with a -10 million donation from the author J K Rowling.The Anne Rowling Regenerative Neurology Clinic at the University of Edinburgh will place patients at the heart of research to improve outcomes for multiple sclerosis sufferers.

2 Sep 2010

Event Pulse report reveals impact of new therapies on MS drug market

The study titled Event Pulse Preview: Multiple Sclerosis shows that 84% of neurologists expect to prescribe Gilenia for some MS patients if approved, but prescribing will likely be limited to second- or third-line therapy until concerns about safety and monitoring requirements are resolved.

1 Sep 2010

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

University of British Columbia researchers have led the development of a new "toolbox of MiniPromoters" for research and future therapies on brain, spinal cord and eye function.

31 Aug 2010

Brain lesion scan appearance shows increased multiple sclerosis activity during spring and summer

New research shows that multiple sclerosis (MS) activity can increase during spring and summer months. The research is published in the August 31, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

31 Aug 2010

SIR issues position statement to determine safety, effectiveness of interventional M.S. treatment

Recognizing that venous interventions may potentially play an important role in treating some patients who suffer from multiple sclerosis an incurable, disabling disease the Society of Interventional Radiology has issued a position statement indicating its support for high quality clinical research to determine the safety and effectiveness of interventional M.S. treatments.

31 Aug 2010

Cell Therapy Foundation analysis calls for funding in medical research

Some of the most promising medical research conducted to treat diseases of the brain, heart, and circulatory system is moving too slowly to help millions of patients, according to the Cell Therapy Foundation, which advocates the use of adult stem cells to dramatically impact and improve the condition of patients who suffer from a variety of conditions.

31 Aug 2010

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

Elan Corporation, plc announced today that Elan's wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., commenced an offer to purchase of up to $186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" together with the 2013 Fixed Rate Notes, the "2013 Notes"),

31 Aug 2010

Cannabis Science seeks entry into European medical cannabis market

Cannabis Science Inc., a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that the Company is currently raising working capital in the European market and pursuing listings on the Frankfurt and other major European exchanges.

30 Aug 2010

Genzyme responds to Sanofi-Aventis' unsolicited acquisition proposal

Genzyme Corp. today confirmed that it has received an unsolicited, non-binding proposal from Sanofi-Aventis to acquire all the outstanding shares of Genzyme for $69 per share in cash. The Genzyme board of directors met last night, unanimously affirmed its previous rejection of Sanofi's proposal, and instructed the company to send Sanofi the following response letter:

30 Aug 2010

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients

Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.

30 Aug 2010

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

The term "macrophage" conjures images of a hungry white blood cell gobbling invading bacteria. However, macrophages do much more than that. Not only do they act as antimicrobial warriors, they also play critical roles in immune regulation and wound-healing. They can respond to a variety of cellular signals and change their physiology in response to local cues.

27 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

26 Aug 2010

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.

26 Aug 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Protagen AG announces € 10.0 Million for second round of finance totaling

Dilemmas created for healthcare professionals by medicinal use of cannabis

'Aspartame danger' myths

Study demonstrates safety of cord blood stem cell transplantation protocol to treat neurological conditions

Benefit of delaying cognitive decline comes at the cost of more rapid dementia progression

CIHR announces recommendations on multiple sclerosis research priorities

New research clinic in Edinburgh to improve outcomes for multiple sclerosis sufferers

Event Pulse report reveals impact of new therapies on MS drug market

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

Brain lesion scan appearance shows increased multiple sclerosis activity during spring and summer

SIR issues position statement to determine safety, effectiveness of interventional M.S. treatment

Cell Therapy Foundation analysis calls for funding in medical research

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

Cannabis Science seeks entry into European medical cannabis market

Genzyme responds to Sanofi-Aventis' unsolicited acquisition proposal

Latest achievements in brain research and treatment for mental disorders

TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in